https://stockcharts.com/h-sc/ui?s=alim&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

https://stockcharts.com/h-sc/ui?s=alim&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

nice

can be big

rip

nice

rip

soon

soon

nice

watching

It establishes where a PT is... and affirms it is a "buy".
You contribute something.

no big deal

ALIM HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $5
BENZINGA

6:20 AM ET 05/19/2023

HC Wainwright & Co. analyst Yi Chen maintains Alimera Sciences (NASDAQ:ALIM) with a Buy and lowers the price target from $9 to $5.

ALIM Added more than double in Pre-Mkt @ 2.16

New avg 2.21.

Hit 3.20 yesterday

I think she still has pep in her step.

https://stockcharts.com/h-sc/ui?s=ALIM

agreed

ALIM I got in for a play

https://stockcharts.com/h-sc/ui?s=ALIM

BRIEF-Alimera Acquires U.S. Commercial Rights To Yutiq®
REUTERS
7:05 AM ET May-18-2023
May 18 (Reuters) - Alimera Sciences Inc (ALIM.NaE):

* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ®

* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ® Source text for Eikon: Further company coverage:


Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alimera Acquires U.S. Commercial Rights to YUTIQ®
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024
Leverages Alimera’s existing U.S. commercial infrastructure
Industry veteran Jason Werner added to Alimera Board of Directors
ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint). A live conference call will be hosted today at 8:30 a.m. ET to provide a corporate update. Please refer to the information in the paragraphs below for conference call dial-in information and webcast registration.

“This is a landmark transaction for Alimera, bringing critical mass to our revenue base and leveraging the commercial infrastructure we have built in the U.S. We know this product very well, having marketed ILUVIEN for the uveitis indication in Europe and the Middle East for several years now. We believe there are immediate synergies in adding YUTIQ to our portfolio that will be accretive to revenue, Adjusted EBITDA and cash flow in the second half of 2023,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “EyePoint has done a wonderful job growing YUTIQ to almost $30 million in revenue in 2022. We believe that deploying a larger commercial team focused on both ILUVIEN and YUTIQ will increase utilization of both products moving forward and expect Alimera to generate in excess of $100 million in net revenue and $20 million in Adjusted EBITDA* in 2024.”

YUTIQ net product revenue increased 60% to $7.4 million in Q1 2023 compared with $4.6 million in Q1 2022. For the full year of 2022, YUTIQ net product revenue increased 67% to $28.3 million compared to $16.9 million in 2021.**

Alimera now has exclusive global rights to YUTIQ excluding China, Hong Kong, Taiwan, Macau, South Korea and Southeast Asia, where EyePoint has a pre-existing license with Ocumension Therapeutics.

Under the terms of the agreement with EyePoint:

Alimera made an upfront cash payment of $75 million at closing; an additional $7.5 million will be paid in equal quarterly installments in 2024.
EyePoint will also receive potential royalties from 2025 to 2028 based on combined net revenues in the U.S. from ILUVIEN and YUTIQ in excess of certain thresholds, beginning at $70 million in 2025 and increasing annually thereafter.
Alimera will immediately assume control of all commercial activities related to YUTIQ in the U.S.
Alimera funded the upfront payment and obtained additional working capital with:

A $69 million private placement of Series B preferred stock and common stock to a syndicate of investors led by Velan Capital and Caligan Partners.
Borrowing of an additional $20 million through an amendment to its existing term loan agreement with SLR Capital Partners, LLC.
“We deeply appreciate the support of SLR Capital and our new shareholders with this transformative transaction for Alimera,” continued Mr. Eiswirth.

Board of Directors Changes

In conjunction with these transactions, Alimera has added Jason Werner to its Board of Directors, as a designee of Velan Capital. Prior to this appointment, long-term board member, Garheng Kong, resigned as director.

“On behalf of the entire board and management, I would like to express our sincerest gratitude to Garheng for his dedication to Alimera for almost twenty years. His committed leadership has played a crucial role in our growth and development as an organization,” said Mr. Eiswirth. “We are fortunate to have Jason joining our Board of Directors, and excited about the ophthalmic and operational experience he brings as we integrate YUTIQ into our portfolio and continue to grow Alimera.”

Mr. Werner currently serves as the Chief Executive Officer of SightStream Biotherapeutics Inc., a biotechnology company focused on developing regenerative medicines in ophthalmics. Mr. Werner also currently serves on the board of directors of InflammX Therapeutics Inc, a privately-held developer of novel treatments of the Inflammasome (NLRP3) Pathway based in San Diego, California. Mr. Werner previously co-founded and served as Chief Operating Officer of Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals Ltd. He has held a variety of Commercial Development roles and Corporate Strategy positions at companies such as Sun Pharma, Nicox SA and Inspire Pharmaceuticals, all within the field of ophthalmics. Mr. Werner received his B.S. in business administration from the University of New Hampshire.

Securities Purchase Agreement

Alimera issued 1,401,901 shares of its common stock and 66,617 shares of its Series B Preferred Stock in exchange for an aggregate of $69 million in gross proceeds. Upon approval by Alimera’s stockholders, the Series B Preferred Stock issued in this second tranche will be mandatorily convertible into 39,186,471 shares of Alimera common stock, subject to adjustment. The purchase price of the common stock and the initial conversion price of this second tranche of Series B Preferred Stock is $1.70 per share. In connection with the funding of this second tranche, the purchasers of the first tranche of Series B Preferred Stock forfeited 4,114,286 of the common stock warrants obtained in connection with the first tranche funding for no consideration.

Amendment to the Loan and Security Agreement

The term loan amendment increased the available amount under the facility from $15 million to $20 million, all of which was funded in connection with the transactions. The maturity date on the facility remains April 30, 2028, with monthly interest-only continuing to May 1, 2025, when principal amortization begins. The interest-only period may be extended an additional 12 months if Alimera achieves $7.5 million in Adjusted EBITDA, as defined in the amended agreement, for any trailing 12-month period ending on or before March 31, 2025. Interest on outstanding borrowing under the term loan is payable at the greater of one-month SOFR or 4.60% plus 5.15% per annum.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. Alimera has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock issued and issuable upon conversion of the Series B Preferred Stock issued in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

* See “Non-GAAP Financial Measures” below.
** According to EyePoint’s SEC reports.

ALIM Call Details – Alimera Corporate Update

Conference Call to Be Held May 18, 2023
A live conference call will be hosted on May 18, 2023, at 8:30 a.m. ET by Rick Eiswirth, President and Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, to discuss Alimera’s financial results and provide an update on corporate developments. Please refer to the information below for conference call dial-in information and webcast registration.

Conference date: Thursday, May 18, 2023, 8:30 a.m. ET
Conference dial-in: 844-839-2190
International dial-in: 412-717-9583
Conference Call Name: Alimera Sciences (Nasdaq: ALIM) Corporate Update Call

Conference Call Pre-registration: Participants are asked to pre-register for the call by navigating to: https://dpregister.com/sreg/10179426/f98ecd113e
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The conference call will also be available through a live webcast which is also available through the company’s website, www.alimerasciences.com in the Events section under Investor Relations.

Live Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=IOhr4gKA
A replay will be available on Alimera’s website, www.alimerasciences.com, under “Investor Relations” one hour following the live call.
Conference Call replay: US Toll Free: 1-877-344-7529
International Toll: 1-412-317-0088
Canada Toll Free: 855-669-9658
Replay Access Code: 8053807
End Date: June 1, 2023
Webcast Replay End Date: August 18, 2023

About Alimera Sciences, Inc.

Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measures

This press release includes forecasted Adjusted EBITDA, which is a non-GAAP financial measure. Alimera uses this measure to supplement the financial information presented on a GAAP basis. Alimera believes that excluding certain items from its GAAP financial results allows management to better understand its ongoing operations and analyze its financial performance from period to period and provides meaningful supplemental information to its investors.

Alimera defines “Adjusted EBITDA” as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, gains on extinguishment of debt, severance expenses and change in fair value of warrant asset.

Alimera believes that Adjusted EBITDA, when taken together with GAAP net income or loss, its most directly comparable GAAP financial measure, provides meaningful supplemental information to investors regarding Alimera’s performance by excluding certain items that may not be indicative of its business, results of operations, or outlook.

This non-GAAP financial measure may not be comparable to similarly titled measures reported by other companies, including companies in Alimera’s industry, because not all companies calculate Adjusted EBITDA in an identical manner or may use other financial measures to evaluate their performance. Therefore, this non-GAAP financial measure may be limited in its usefulness for comparison between companies. The presentation of this non-GAAP financial measure is not intended to be considered in isolation from or as a substitute for other financial performance measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, non-GAAP financial measures are subject to inherent limitations because they reflect the exercise of judgments by management. Investors are encouraged not to rely on any single financial measure to evaluate Alimera’s business.

Alimera’s anticipated consolidated net revenue and Adjusted EBITDA is based on information available as of May 18, 2023 and expected cost savings and synergies, In addition, such forecasts assume foreign exchange rates prevailing as of March 31, 2023.

Alimera has relied upon the exception in item 10(e)(1)(i)(B) of Regulation S-K and has not provided a quantitative reconciliation of forecasted Adjusted EBITDA to forecasted GAAP net income or loss, its most directly comparable GAAP financial measure, within this press release because Alimera is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, income taxes which are directly impacted by unpredictable fluctuations in the market price of Alimera's stock. These statements are forward-looking and actual results may differ materially. Refer to “Forward Looking Statements” below for information on the factors that could cause Alimera's actual results to differ materially from these forward-looking statements.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations with respect to its future operating and financial results and the expected cost savings and synergies resulting from the YUTIQ acquisition and foreign exchange rates. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties (some of which are beyond Alimera’s control), including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in these forward-looking statements. Other factors are discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s most recently filed Quarterly Report on Form 10-Q, most recently filed Annual Report on Form 10-K, and any of Alimera’s subsequent filings with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely on the forward-looking statements Alimera makes or that are made on its behalf as predictions of future events. These forward-looking statements speak only as of the date of this press release. Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com
For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com


https://www.globenewswire.com/newsroom/ti?nf=ODg0MjA0NCM1NjAyNDk1IzIwMDQwMTM=
https://ml.globenewswire.com/media/MjA2MTY0MzAtYzljZC00N2E2LWFmOTItZTAyYWVmOGFhMWRjLTEwMTU1ODY=/tiny/Alimera-Sciences-Inc-.png

Source: Alimera Sciences, Inc.
© 2023 GlobeNewswire, Inc.

ALIM chart

It was a CEO just picked up 125,000 worth in chairs on Friday think something up

With our aging population, Macular Degeneration (MD) and vision loss is becoming a significant contributor to the rise in medical costs for Medicare.

Monitoring companies like ALIM and CUBT (very early play) that have promising therapies for MD. These stocks will move when clinical trials start and/or clinical results that are promising are announced.

JMO

Merry Christmas $$$$$$:$

makes ya wonder how some stocks get 100M volume plus and ALIM is super low volume on news


hmmmm

30.00

ALIM--Looking Good in the Field of Vision




Bullet Points

*Focused on Retinal Disease

*Diabetic Macular Edema(DME) is leading cause of vision loss in diabetic patients.

*Product 'Iluvien" - continuous micro-dosing to the eye for patients

*Company launching selected markets worldwide



Background:

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

www.alimerasciences.com.

News: $ALIM LD Micro Announces Preliminary List of Presenters for the LD 500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

Read the whole news ALIM - LD Micro Announces Preliminary List of Presenters for the LD 500

ALIM surprises on Earnings. Gapping higher in the morning.

ALIM reported 2nd qtr 2020 earnings of $-0.51 per share on 7/29/20. This beat the $-1.62 consensus of the 2 analysts covering the company.
Surprise %:
68.4%

Surprise:
$1.105

ALIM Chart

Alimera Sciences Overview


Ticker: ALIM
Current Price: $6.10
Market Cap: $29 million

Bullets:
*Focused on Retinal Disease
*Diabetic Macular Edema(DME) is leading cause of vision loss in diabetic patients.
*Product 'Iluvien" - continuous micro-dosing to the eye for patients
*Company launching selected markets worldwide
*2019 Revenues = $53.9 mm (Up 16% from 2018)
*1st Qtr 2020 revenues up 12% vs. same period in '19
*$12 million cash as of 3/31/2020

Background:

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

www.alimerasciences.com.

News: $ALIM Alimera Sciences Initiates Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

A randomized, controlled , multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care Company to host Conference Call on July 15, 2020 to discuss study protocol and implicati...

Got this from ALIM - Alimera Sciences Initiates Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
Date : 12/04/2019 @ 8:30AM
Source : GlobeNewswire Inc.
Stock : Alimera Sciences Inc (ALIM)
Quote : 9.1 1.58 (21.01%) @ 5:19PM
Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019


Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will be a featured presenter at the LD Micro Main Event on Tuesday, December 10, 2019 at 12:40 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Mr. Eiswirth will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings. In addition, his presentation will be webcast. To access the webcast, please visit http://wsw.com/ldmicro17/alim at the time of the presentation. The webcast will also be archived for 90 days and may be subsequently accessed on the Company’s website. For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

About ILUVIEN®

The Company’s primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye. With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The 17 European countries include the U.K., Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the Netherlands, and Luxembourg. The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize the label for the new indication to meet each country’s local requirements. Timeline to this goal varies by each country, and the non-infectious posterior uveitis indication for ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is not approved for treatment of uveitis in the United States.

For press inquiries: For investor inquiries:
Jules Abraham Scott Gordon
for Alimera Sciences for Alimera Sciences
917-885-7378 scottg@coreir.com

COULD BE HUGE, BUYOUT COMING ????? Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019 GlobeNewswire Inc. - 12/4/2019 8:30:10 AM

GOOD EVENING FRIEND/ WOW WOWZER HITTER FER US'INS. ALIM 9.10 +1.58 +21.01% USD 4:00PM EST 185,525

wow wowzer read peter/\Alimera Sciences (ALIM) Announces Regulatory Approval for ILUVIEN in Benelux Countries for Treatment of Non-Infectious Posterior Uveitis

https://www.streetinsider.com/Corporate+News/Alimera+Sciences+%28ALIM%29+Announces+Regulatory+Approval+for+ILUVIEN+in+Benelux+Countries+for+Treatment+of+Non-Infectious+Posterior+Uveitis/16202783.html


Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the governmental agencies that oversee the availability of medical products in Belgium, The Netherlands and Luxembourg, collectively known as the Benelux countries, have each granted marketing authorization for ILUVIEN® for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

The complete Benelux approval was achieved when The Netherlands’ Medicines Evaluation Board informed Alimera of their approval on November 6, 2019. The approval by Belgium’s Federal Agency for Medicines and Health Products was received in May of 2019, and Luxembourg’s Heads of Medicines Agencies provided its confirmation of regulatory approval in late October. Alimera announced in September that it was expanding its relationship with French distribution partner, Horus Pharmaceuticals, who will help the Company achieve reimbursement in all three countries, after which it will oversee distribution throughout Benelux for the new indication.

“We are pleased to now have the approvals for this new indication for ILUVIEN across Benelux so that our partner, Horus Pharmaceuticals, can now pursue reimbursement in each of these markets for both diabetic macular edema and posterior segment non-infectious uveitis,” said Rick Eiswirth, president and CEO of Alimera.

“Following a strong launch in France for diabetic macular edema,
we are excited to see what Horus can do with ILUVIEN in these countries, providing us with additional markets in Europe where we believe ILUVIEN can help physicians control the recurrence of disease in patients who have either of these conditions.”

See http://www.ILUVIEN.com for important safety information.

News: $ALIM Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick...

Find out more ALIM - Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

$ALIM https://www.streetinsider.com/Corporate+News/Alimera+Sciences+%28ALIM%29+Announces+Regulatory+Approval+for+ILUVIEN+in+Benelux+Countries+for+Treatment+of+Non-Infectious+Posterior+Uveitis/16202783.html

People Wanting This Treatment "THE RIGHT TO TRY"/\Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
GlobeNewswire GlobeNewswire•December 4, 2019

ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE)
-- Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader
in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,

today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will be a featured presenter at the LD Micro Main Event on
Tuesday, December 10, 2019 at 12:40 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Mr. Eiswirth will provide an overview of the company’s business
model and growth strategy and will be available for one-on-one meetings.

In addition, his presentation will be webcast. To access the webcast, please visit

http://wsw.com/ldmicro17/alim at the time of the presentation.

The webcast will also be archived for 90 days and may be subsequently accessed on the Company’s website.

For those interested in attending or for registered attendees who wish to request meetings,
please contact David Scher at david@ldmicro.com or visit
http://www.ldmicro.com for more information.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.

Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.

For more information, please visit http://www.alimerasciences.com.

About ILUVIEN®

The Company’s primary product is ILUVIEN
(fluocinolone acetonide intravitreal implant)
0.19 mg sustained release intravitreal implant,
injected into the back of the eye.

With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide,

a corticosteroid, for 36 months,
to reduce the recurrence of disease,
enabling patients to maintain vision longer with fewer injections.

ILUVIEN is approved in the
U.S.,
Canada,
Kuwait,
Lebanon and
the U.A.E
to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure.

In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered
insufficiently responsive to available therapies.

In March 2019, ILUVIEN received approval in the 17 countries under
the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

The
17 European countries include the
U.K.,
Germany,
France,
Italy,
Spain,
Portugal,
Ireland,
Austria,
Belgium,
Denmark,
Norway,
Finland,
Sweden,
Poland,
Czech Republic,
the Netherlands, and
Luxembourg.

The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize
the label for the new indication to meet each country’s local requirements.

Timeline to this goal varies by each country,
and the non-infectious posterior uveitis indication for ILUVIEN
was launched in
Germany and
the U.K. in 3Q 2019.

ILUVIEN is not approved for treatment of uveitis in the United States.

For press inquiries:

For investor inquiries:
Jules Abraham Scott Gordon
for Alimera Sciences for Alimera Sciences
917-885-7378 scottg@coreir.com
julesa@coreir.com

wow/\ $ALIIM/


wow/\ $ALIIM/ [-chart]ih.advfn.com/p.php?pid=staticchart&s=ALIM&p=0&t=17&width=336&height=112&vol=1&min_pre=180[/chart]

even higher/\ALIM 7.09 +0.26 +3.81% USD 9:55AM EST 47,624

maybe buyout peter. huge rewards from $0.20 pps/\

WOW, ALIM
Bid: 6.63 Ask: 6.79 Last: 6.67 Chg ($): 1.0106 Vol:

https://otcbb.swingtradebot.com/equities/ALIM, WOW

ALIM 5.58 +0.60 +12.05% USD 10:45AM EST 57.420k and higher now.

'ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendment to its restated certificate with the Secretary of State of the State of Delaware that will effect the previously announced one-for-15 reverse stock split of its common stock. The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. On November 15, 2019, Alimera’s common stock will begin trading on a post-reverse stock split basis on The Nasdaq Global Market under the existing symbol “ALIM.”

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

Forward-Looking Statements

This press release contains a “forward-looking statement” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Alimera’s expectation that its common stock will trade The Nasdaq Global Market on a post-reverse stock split basis on November 15, 2019. The forward-looking statement is based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change this expectation, and could cause actual results to differ materially from those projected in the forward-looking statement. Meaningful factors that could cause actual results to differ include, but are not limited to, unforeseen technical issues that could result in Alimera’s common stock not trading on The Nasdaq Global Stock Market on a post-reverse stock split basis on November 15, 2019 as expected.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com

For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com

good morning, 11-15-2019 /\'Alimera Sciences (ALIM)'

indeed peter, wow last couple of days. 'Alimera Sciences (ALIM)'

Nice close

News: $ALIM Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendme...

Find out more ALIM - Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

kind ah nice to make 50% on couple day trade/\'Alimera Sciences (ALIM)'

$ALIM GAPPER tomorrow!!!! Added more before bell, but how much ?????


'Alimera Sciences (ALIM)'